{"id":405659,"date":"2020-12-27T21:46:07","date_gmt":"2020-12-28T02:46:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=405659"},"modified":"2020-12-27T21:46:07","modified_gmt":"2020-12-28T02:46:07","slug":"innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/","title":{"rendered":"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma"},"content":{"rendered":"

<\/p>\n

InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma <\/b><\/p>\n

BEIJING–(BUSINESS WIRE<\/a>)–
\nInnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) \/small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed\/refractory mantle cell lymphoma (MCL). Both new drug applications (NDAs) were previously granted priority review by the Center for Drug Evaluation (CDE) of the NMPA.\n<\/p>\n

\n\u201cI would like to thank our entire team at InnoCare for their hard work and contributions,\u201d said Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare. \u201cThis approval marks the maturation of InnoCare from a clinical to a commercial stage company.\n<\/p>\n

\n\u201cThe approval of orelabrutinib would not have been possible without the strong support from our partners, physicians, experts and patients who participated in a series of clinical trials,\u201d said Dr. Cui. \u201cScience drives innovation for the benefit of patients. From the initial R&D to patients, orelabrutinib has gone through an extraordinary journey. Treatment with orelabrutinib has demonstrated clear benefit for patients. We remain highly focused on the development of additional high-quality innovative drugs that can address unmet needs.\u201d\n<\/p>\n

\nOrelabrutinib is a BTK inhibitor developed by InnoCare for the treatment of cancer and autoimmune diseases.\n<\/p>\n

\n\u201cCompared with other BTK inhibitors, orelabrutinib shows a higher complete response (CR) rate in the treatment of relapsed\/refractory (R\/R) CLL\/SLL patients, and we expect even deeper responses with a longer treatment of patients with orelabrutinib,\u201d said Jianyong Li, M.D., Professor and Director of the Department of Hematology and Director of the Pukou CLL Center at the First Affiliated Hospital of Nanjing Medical University. \u201cWe believe that the approval of orelabrutinib will provide a safe and effective new treatment solution for lymphoma patients in China.\u201d\n<\/p>\n

\n\u201cData from trials with orelabrutinib have shown sustained efficacy in the treatment of R\/R MCL patients,\u201d said Jun Zhu, M.D., Ph.D., Professor and Director of the Department of Internal Medicine and Lymphoma, Peking University Cancer Hospital. \u201cWe believe the improved safety profile resulting from high selectivity and the convenience of daily oral administration will help make orelabrutinib a favorable treatment option for patients of B-cell malignancies.\u201d\n<\/p>\n

\nChina represents a large pharmaceutical market. The development of novel drugs requires focused drug discovery efforts, world-class research and development capabilities, state-of-the-art clinical research and significant capital investment.\n<\/p>\n

\n“Continuous breakthroughs in life science technology are the foundation for the sustainable development of China’s healthcare industry in the future,\u201d said Professor Yigong Shi, the co-founder and President of the Science Advisory Board (SAB) of InnoCare. \u201cTo promote the research and development of innovative drugs such as orelabrutinib, cutting-edge science is essential, and it is equally critical to integrate collaborations among industry, academia, research institutions and hospitals. By doing so, R&D can keep up with rapidly evolving market needs. At present, although science and technology continue to evolve, we are still far from defeating malignant tumors and autoimmune diseases. I sincerely believe that more innovative companies will emerge in China and make greater contributions to the development of China’s healthcare system.”\n<\/p>\n

\nLymphoma is a malignant tumor that originates from the lymphoid hematopoietic system. Relevant data show that lymphoma is one of the malignant tumors with the fastest growth of incidence rate and one of the top ten malignant tumors with the highest mortality rate in China. Every year, approximately 93,000 people are newly diagnosed with lymphoma, and more than 50,000 people die from it1<\/sup>. BTK is a key kinase of the B cell receptor (BCR) signaling pathway and an important regulator of B cell proliferation and survival mainly in non-Hodgkin’s lymphoma (NHL). BTK inhibitors can block BCR-induced BTK activation and downstream signaling pathways, thereby inhibiting the growth of B-cell tumors and promoting cell apoptosis.\n<\/p>\n

\nOrelabrutinib is a highly selective and novel BTK inhibitor developed by InnoCare that can avoid off-target-related adverse events with improved safety and efficacy.\n<\/p>\n

\nAbout the latest clinical date of orelabrutinib, please refer to: https:\/\/cn.innocarepharma.com\/en\/media\/press-release\/20201208\/<\/a><\/p>\n

About InnoCare<\/b><\/p>\n

\nInnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and\/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.\u00a0\n<\/p>\n

\n

1<\/sup> Source: https:\/\/baijiahao.baidu.com\/s?id=1677968646475994848&wfr=spider&for=pc<\/a><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201227005017\/en\/<\/a><\/span><\/p>\n

\u8054\u7cfb\u4eba
\n<\/b>
\u5a92\u4f53
\n<\/b>
Chunhua Lu
\n
\u9646\u6625\u534e
\n
86-10-66609879
\n
chunhua.lu@innocarepharma.com <\/a><\/p>\n

\u6295\u8d44\u8005
\n<\/b>
86-10-66609999
\n
ir@innocarepharma.com<\/a><\/p>\n

KEYWORDS:<\/b> China Asia Pacific<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma BEIJING–(BUSINESS WIRE)– InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) \/small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed\/refractory mantle cell lymphoma (MCL). Both new drug applications (NDAs) were previously granted priority review by the Center for Drug Evaluation (CDE) of the NMPA. \u201cI would like to thank our entire team at InnoCare for their hard work and contributions,\u201d said Dr. Jasmine Cui, the … <\/p>\n

Continue reading “InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-405659","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma BEIJING–(BUSINESS WIRE)– InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) \/small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed\/refractory mantle cell lymphoma (MCL). Both new drug applications (NDAs) were previously granted priority review by the Center for Drug Evaluation (CDE) of the NMPA. \u201cI would like to thank our entire team at InnoCare for their hard work and contributions,\u201d said Dr. Jasmine Cui, the … Continue reading "InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-28T02:46:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201227005017r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\\\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\\\/Refractory Mantle Cell Lymphoma\",\"datePublished\":\"2020-12-28T02:46:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/\"},\"wordCount\":839,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201227005017r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/\",\"name\":\"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\\\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\\\/Refractory Mantle Cell Lymphoma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201227005017r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-12-28T02:46:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201227005017r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201227005017r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\\\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\\\/Refractory Mantle Cell Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/","og_locale":"en_US","og_type":"article","og_title":"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma - Market Newsdesk","og_description":"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma BEIJING–(BUSINESS WIRE)– InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) \/small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed\/refractory mantle cell lymphoma (MCL). Both new drug applications (NDAs) were previously granted priority review by the Center for Drug Evaluation (CDE) of the NMPA. \u201cI would like to thank our entire team at InnoCare for their hard work and contributions,\u201d said Dr. Jasmine Cui, the … Continue reading \"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-28T02:46:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201227005017r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma","datePublished":"2020-12-28T02:46:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/"},"wordCount":839,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201227005017r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/","name":"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201227005017r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-12-28T02:46:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201227005017r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201227005017r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innocare-announces-the-approval-of-orelabrutinib-in-china-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-and-relapsed-refractory-mantle-cell-lymphoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed\/Refractory Mantle Cell Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=405659"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/405659\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=405659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=405659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=405659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}